Fortune 500 giant will open bioanalytical laboratory in Gothenburg
Thermo Fisher Scientific will expand its bioanalytical presence in Europe and has chosen Gothenburg, Sweden, as a base for its expansion of support services in drug development. A new bioanalytical laboratory, creating up to 140 new jobs for researchers and laboratory staff, will be established during the last quarter of 2025.
The PPD™ clinical research business of Thermo Fisher Scientific will expand its lab footprint in Europe, with a new lab in Gothenburg, located in GoCo Health Innovation City, just south of AstraZeneca's R&D facility. It will cover 2,700 square meters and employ up to 140 highly skilled individuals.
"We are delighted that this major employer will establish a large-scale facility in the Gothenburg region, creating knowledge-intensive jobs in our growing life science sector. The fact that Thermo Fisher Scientific has chosen Gothenburg for its European expansion is a sign of strength for us as a region," says Patrik Andersson, CEO of Business Region Göteborg.
Gothenburg has a life science community of over 600 companies. Many of them are involved in drug development, in different phases having different roles. Many are potential collaborative partners of Thermo Fisher Scientific, whose services support the entire medical development journey, clinical trials and commercialization.
"The company's offering in lab services and support linked to drug development matches very well with our ecosystem, and we are pleased with our excellent relationship with Thermo Fisher Scientific. In addition to AstraZeneca, we have many exciting smaller companies in drug development here in Gothenburg, many with a focus on advanced therapies and regenerative medicine," says Iris Öhrn, Investment Advisor at Business Region Göteborg.
The entry of Thermo Fisher Scientific into the region, and the resulting collaborations, will increase the importance of the region in the life science sector, she reasons.
Thermo Fisher Scientific, the world leader in serving science, has annual revenue of more than USD 40 billion and is headquartered in Massachusetts. The company’s focus includes supporting the development and commercialization of all types of drugs and therapies, supplying most major companies in the pharmaceutical and biotech industry. The company is on the Fortune 500, the list of America's largest companies. The company already has a small logistics and service center in Gothenburg. In 2023 the group employed around 122,000 employees.
“We are thrilled to expand our bioanalytical footprint in Europe – in the collaborative and innovative environment of GoCo Health Innovation City – as we deploy the most technologically advanced systems to develop assays supporting early discovery and subsequently apply them for testing of clinical trial samples across every stage of drug development for our customers,” said Leon Wyszkowski, president, analytical services, clinical research, Thermo Fisher Scientific. “Our presence in Sweden will support our customers with accurate and timely data, empowering them to make informed decisions, as we advance Thermo Fisher’s Mission to enable our customers to make the world healthier, cleaner and safer.”
Read also the press release from Thermo Fisher Scientific.